Neuromodulation Market Key Players and Opportunities by 2027

Historic Data: 2017-2018   |   Base Year: 2019   |   Forecast Period: 2020-2027
  • Status : Published
  • Report Code : TIPAR100001415
  • Category : Life Sciences
  • No. of Pages : 195
  • Available Report Formats : pdf-format excel-format
Buy Now
Neuromodulation Market Key Players and Opportunities by 2027
Report Date: Oct 2020   |   Report Code: TIPAR100001415 Email: sales@theinsightpartners.com
Buy Now

The Neuromodulationmarket was valued at US$ 7,613.45 million in 2019 and is projected to reach US$ 16,333.98 million by 2027; it is expected to grow at a CAGR of 10.3%during 2020–2027.

Neurological disorders such as cerebrovascular diseases, Alzheimer’s disease, and Parkinson's disease can be treated with the help of neuromodulation that is performed by using various devices or infusing drugs. Devices used in neuromodulation Market involve the application of electrodes to the spinal cord, brain, or peripheral nerves.

Market Insights

Increasing Incidence of Neurological Disorders Drives Market Growth

Depression is the most common neurological disorder among all age groups. In the developing regions, most people suffer from depression owing to various socioeconomic factors such as financial stress and poverty. Other neurological disorders such as dystonia, Parkinson’s disease, and obsessive-compulsive disorder are usually observed in aging population. According to a study ‘Incidence and Prevalence of Major Neurologic Disorders,’ published in January 2018, ~36% of elderly have moderate or severe memory impairment in the US. Each year nearly 1.2 million adults are diagnosed with brain disorders, of which 51.3% is due to stroke and 21% due to Alzheimer’s disease. In addition, nearly 135 million people are diagnosed with Parkinson’s disease, traumatic brain injury, and epilepsy each year. Moreover, ~500,000 cases of brain tumor, multiple sclerosis, and amyotrophic lateral sclerosis are reported annually. Therefore, the growing prevalence of neurological disorders is consequently propelling the demand for neuromodulators as these help in relieving neurological symptoms. Furthermore, the rising demand for neurostimulation devices to treat chronic pain.

Customize This Report To Suit Your Requirement

Get FREE CUSTOMIZATION

Published Report - Neuromodulation Market: Strategic Insights

global-neuromodulation-report
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Products Insights

In terms of technology, the external (non-invasive) neuromodulation segment held a greater share of the neuromodulation market in 2019. The same segment is expected to continue its dominance  and register a higher CAGR in the market during the forecast period.

Application Insights

Based on application, the global neuromodulation market is segmented into chronic pain management, failed back syndrome, epilepsy, tremor, incontinence, depression, dystonia, gastroparesis, Parkinsons’s disease, obsessive-compulsive disorder, and migraine. The chronic pain management segment held the largest share of the market in 2019, and it is expected to register the highest CAGR during the forecast period.

Chronic pain management helps relieve pain with the use of drugs, therapies, and lifestyle changes. Electrical stimulation devices play a major role in pain management as they are primarily developed for relieving several types of chronic and acute pain.Growing geriatric population, increasing chronic condition prevalence, and sedentary lifestyle are a few of the risk factors that may cause chronic pain. For instance, according to a study published by Arthritis Foundation in 2019, aging population is responsible for the growing prevalence of all types of diseases across the world. The same study stated that1 in 3 people in the US suffers from arthritis each year. Therefore, the rising prevalence of chronic pain is expected to drive the growth of the segment during the forecast period.

The incorporation of advanced technologies in electrical stimulation devices enables additional benefits for pain management. For instance, in January 2019, Abbott announced test results of BurstDR stimulation developed for the treatment of chronic pain. The results show thatthe product reduces pain by around 60–70%.

Players operating in the neuromodulation market adopt collaboration and partnership strategies to meet demands of end users through the introduction of technologically advanced offerings, and these strategies  significantly support the growth of the market. 

Neuromodulation

Published Report - Neuromodulation Market Report Scope

Report Attribute Details
Market size in 2019 US$ 7.61 Billion
Market Size by 2027 US$ 16.33 Billion
Global CAGR (2019 - 2027) 10.3%
Historical Data 2017-2018
Forecast period 2020-2027
Segments Covered By Technology
  • External Neuromodulation
  • Internal Neuromodulation
By Application
  • Chronic Pain Management
  • Failed Back Syndrome
  • Epilepsy
  • Tremor
  • Incontinence
  • Depression
  • Dystonia
  • Gastroparesis
  • Parkinson Disease
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Abbott
  • Boston Scientific Corporation
  • Medtronic
  • NeuroPace, Inc.
  • NeuroSigma, Inc.
  • NEVRO CORP.
  • Synapse Biomedical Inc.
  • Soterix Medical Inc
  • Integer Holdings Corporation
  • Magstim

Published Report - Neuromodulation Market Players Density: Understanding Its Impact on Business Dynamics

The Published Report - Neuromodulation Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

global-neuromodulation-report-cagr

By Technology

  • External (Non-Invasive) Neuromodulation
    • Respiratory Electrical Stimulation
    • Transcutaneous Electrical Nerve Stimulation
    • Transcranial Magnetic Stimulation
  • Internal Neuromodulation
    • Deep Brain Stimulation
    • Sacral Nerve Stimulation
    • Gastric Electrical Stimulation
    • Spinal Cord Stimulation
    • Vagus Nerve Stimulation

By Application

  • Chronic Pain Management
  • Failed Back Syndrome
  • Epilepsy
  • Tremor
  • Incontinence
  • Depression
  • Dystonia
  • Gastroparesis
  • Parkinson’s Disease
  • Obsessive-Compulsive Disorder
  • Migraine

By End User

  • Hospitals
  • Clinics
  • Home Healthcare

By Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • UK
    • Russia
  • Asia Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
  • South and Central America
    • Brazil
    • Argentina

Company Profiles

  • Abbott
  • Boston Scientific Corporation
  • Medtronic
  • NeuroPace, Inc.
  • NeuroSigma, Inc.
  • NEVRO CORP.
  • Synapse Biomedical Inc.
  • Soterix Medical Inc
  • Integer Holdings Corporation
  • Magstim 

Frequently Asked Questions

The high cost of neuromodulation devices is the significant factor that will hinder the neuromodulation market growth.

The global neuromodulation market is being driven by factors such as increasing incidence of neurological disorders, growing developments in neuromodulation technology. Furthermore, rising demand for neurostimulation devices to treat chronic pain is likely to offer significant opportunities for the growth of the global neurostimulation market.

Neuromodulation is the process of regulating the activity of nerves by controlling the physiological level of neurotransmitters. These modifications are brought about with the help of various devices or by drug infusion. These devices contain small electrodes that are placed on the spinal cord, brain or the peripheral nerves. Neurological disorders such as, cerebrovascular diseases, Alzheimer disease and Parkinson's disease affect the neurological functioning of the body and hence can be treated with the help of neuromodulation.
Mrinal Kerhalkar
Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

  • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
  • PEST and SWOT Analysis
  • Market Size Value / Volume - Global, Regional, Country
  • Industry and Competitive Landscape
  • Excel Dataset

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
☀️ Eligible for Summer Discount
Unlock Exclusive Report Discounts
Enquire Now
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
Chat with us
DUNS Logo
ISO Certified Logo
GDPR
CCPA
Page Updated: Jun 2024